Transgenomic Opens Pharmacogenomics Laboratory in China

Provides New Opportunity to Serve Pharmaceutical Partner Interest for Clinical
Trials in China

OMAHA, Neb., March 31 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
(OTC Bulletin Board: TBIO), a global genetic analysis and services company,
today announced that it has entered into a laboratory services agreement with
the Guangzhou Family Planning Center in Guangzhou, China. Under this
agreement, Transgenomic will partner with the Guangzhou Laboratory to provide
pharmacogenomic analyses within the Guangzhou Laboratory for pharmaceutical
companies who choose to pursue clinical trials in China. The company has
already equipped the facility with the instrument system technology needed to
provide these sophisticated pharmacogenomics services.
"Our partnership with the Guangzhou laboratory, coupled with our expanding
expertise in conducting pharmacogenomics studies for pharmaceutical companies
opens a new door of opportunity for our Pharmacogenomics business," said Craig
Tuttle, Transgenomic President and Chief Executive Officer. "Many of our
Pharmaceutical partners are interested in pursuing clinical trials in China.
Under Chinese law, samples collected in China must be tested in China. The
Guangzhou laboratory provides the facility to enable us to offer our
Pharmaceutical customers the testing capabilities they seek as they expand
their clinical trial efforts to Asia, opening significant new clinical testing
opportunities for us and strengthening our position as a leading supplier to
our pharmaceutical partners in their worldwide efforts to bring new drugs to
market."
About Transgenomic:
Transgenomic is a global biotechnology company that provides unique
products and services for automated high sensitivity genetic variation and
mutation analysis. Their offerings include systems, products, discovery and
laboratory testing services to the academic and medical research, clinical
laboratory and pharmaceutical markets in the fields of pharmacogenomics and
personalized medicine. Specific offerings include WAVE(R) DHPLC Systems,
related consumables and assay kits, cytogenetics automated systems,
Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics
Research Services. Transgenomic's two laboratory services divisions utilize
these technologies and expertise to provide a menu of mutation scanning tests
for over 700 cancer-associated genes and more than 60 validated diagnostic
tests to meet the needs of pharmaceutical and biotech companies, research and
clinical laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please
visit: http://www.transgenomic.com.
Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include,
but are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the Company to
grow its involvement in the diagnostic products and services markets. The
known risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly, the company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press release. All information in this
press release is as of the date of the release and Transgenomic does not
undertake any duty to update this information, including any forward-looking
statements, unless required by law.
SOURCE Transgenomic, Inc.

Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5446, dschneider@transgenomic.com